Hate to burst too many commercial activities excitement…appears to be a common statement. Here is one from 2017 for instance.
I’m sure there would be many more if someone wanted to look!
“Biotron's Managing Director, Dr Michelle Miller commented: "Whilst Biotron is fully funded for its current activities, which include the upcoming Phase 2 HIV-1 trial (BIT225-009), this R&D cash rebate will strengthen the Company's cash position and support commercialisation activities.
Hate to burst too many commercial activities excitement…appears...
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.72M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.4¢ | 5.2¢ | $2.393K | 44.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19600 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 188178 | 2 |
View Market Depth
| Last trade - 15.15pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.4¢ |
Change
0.000 ( 3.85 %) |
||||
| Open | High | Low | Volume | ||
| 5.4¢ | 5.4¢ | 5.2¢ | 120722 | ||
| Last updated 15.15pm 03/05/2024 ? | |||||
| BIT (ASX) Chart |